Busulfan clinical trials
Also written Busulfex and Busilvex.
Related medicines add 1 study
Counted the way a researcher would: Busulfan with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Busulfan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Busulfan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Jun 1954 · MYLERAN · NDA 009386 (FDA, Drugs@FDA)
- European Union
- 9 Jul 2003 · Busilvex · EMEA/H/C/000472 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
312 studies that test it; most in 2007 (19); 4 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 2 |
| 1993 | 2 |
| 1995 | 3 |
| 1996 | 2 |
| 1997 | 5 |
| 1998 | 8 |
| 1999 | 5 |
| 2000 | 13 |
| 2001 | 4 |
| 2002 | 12 |
| 2003 | 7 |
| 2004 | 13 |
| 2005 | 16 |
| 2006 | 13 |
| 2007 | 19 |
| 2008 | 11 |
| 2009 | 16 |
| 2010 | 17 |
| 2011 | 17 |
| 2012 | 18 |
| 2013 | 15 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 14 |
| 2017 | 7 |
| 2018 | 16 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 314
M.D. Anderson Cancer Center (42) · Masonic Cancer Center, University of Minnesota (20) · Fred Hutchinson Cancer Center (20) · Memorial Sloan Kettering Cancer Center (15) · University of California, San Francisco (10) · National Cancer Institute (NCI) (9) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · City of Hope Medical Center (9)
Often tested with
Tested in the same studies.
Fludarabine (149) · Cyclophosphamide (113) · Melphalan (88) · Fludarabine phosphate (49) · Antilymphocyte Serum (36) · Thiotepa (35) · Etoposide (30) · Tacrolimus (30)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Busulfan is the comparator. A study of two new drugs counts under both.
- 2Melphalan · Wuhan Union Hospital, China, St. Anna Kinderkrebsforschung
- 1Bomedemstat · Merck Sharp & Dohme LLC · next primary completion Jul 2027
- 1Fludarabine · Wuhan Union Hospital, China
- 1Vincristine · St. Anna Kinderkrebsforschung
- 1Dinutuximab · St. Anna Kinderkrebsforschung
- 1Carboplatin · St. Anna Kinderkrebsforschung
- 1Etoposide · St. Anna Kinderkrebsforschung
- 1Cisplatin · St. Anna Kinderkrebsforschung
Reaching primary completion within a year · 13, 1 in phase 3
Studies that test Busulfan, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Nov 2026Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesPhase 2 · University of Illinois at Chicago
- Dec 2026HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyPhase 2 · Children's Hospital Medical Center, Cincinnati
- Dec 2026Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisPhase 2 · Center for International Blood and Marrow Transplant Research
- Jan 2027Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersPhase 2 · Masonic Cancer Center, University of Minnesota
- Apr 2027A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantPhase 2 · Memorial Sloan Kettering Cancer Center
- May 2027Personalized NK Cell Therapy in CBTPhase 2 · M.D. Anderson Cancer Center
- Jul 2027Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaPhase 1 · City of Hope Medical Center
- Aug 2027Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studies
Open first, then newest update. How each study uses Busulfan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 318
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as BusulfanHow we know
- 26DT052; Scaling Busulfan Dose to Body Surface Area in ChildrenNot yet recruitingPhase 1Children's Hospital of PhiladelphiaNCT07792369Written as Busulfan (BU)How we know
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as BusulfanHow we know
- Personalized NK Cell Therapy in CBTRecruitingPhase 2M.D. Anderson Cancer CenterNCT02727803Written as BusulfanHow we know
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as BusulfanHow we know
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07775313Written as BusulfanHow we know
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT06954987Written as BusulfanHow we know
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingPhase 2Fred Hutchinson Cancer CenterNCT03970096Written as BusulfanHow we know
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingPhase 2National Cancer Institute (NCI)NCT01861106Written as Busulfan (Busulfex)How we know
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06851767Written as BusulfanHow we know
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNot applicableGuenther KoehneNCT05617625Written as BusulfanHow we know
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingPhase 2Guenther KoehneNCT05565105Written as BusulfanHow we know
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743Written as BusulfanHow we know
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaRecruitingPhase 2/3St. Anna KinderkrebsforschungNCT01949129Written as BusulfanHow we know
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as BusulfanHow we know
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07762508Written as Busulfan (BU)How we know
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingPhase 2/3M.D. Anderson Cancer CenterNCT04708054Written as BusulfanHow we know
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06959771Written as BusulfanHow we know
- Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingPhase 2University of Illinois at ChicagoNCT06802315Written as Busulfan (conditioning for ALLO Transplant)How we know
- Haplo-Cord HSCT for AML/MDSRecruitingNot applicableFujian Medical University Union HospitalNCT07588360Written as Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)How we know
See all 318 studies that test Busulfan →
Given beside what is tested · 111 — Busulfan is usual care or a partner of the new treatment
- A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple SclerosisNot yet recruitingPhase 1Orca Biosystems, Inc.NCT06900192Written as myeloablative regimenHow we know
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT01306019Written as BusulfanHow we know
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as BusulfanHow we know
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingPhase 1University of Michigan Rogel Cancer CenterNCT07737769Written as BusulfanHow we know
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as BusulfanHow we know
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as BusulfanHow we know
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as BusulfanHow we know
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingPhase 2National Cancer Institute (NCI)NCT05027945Written as BusulfanHow we know
- Gene Editing For Sickle Cell DiseaseRecruitingPhase 1St. Jude Children's Research HospitalNCT06506461Written as BusulfanHow we know
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) AntagonistsRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05463133Written as BusulfanHow we know
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06345495Written as BusulfanHow we know
- Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)RecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07183878Written as Busulfan (BU)How we know
- Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic MalignanciesRecruitingPhase 1Sawa Ito, MDNCT07565220Written as BusulfanHow we know
- Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple MyelomaNot yet recruitingPhase 1University of California, DavisNCT07759102Written as BusulfanHow we know
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as BusulfanHow we know
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)RecruitingNot applicableMasonic Cancer Center, University of MinnesotaNCT01666080Written as BusulfanHow we know
- Allo HSCT for High Risk HemoglobinopathiesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06872333Written as BusulfanHow we know
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingPhase 2Nantes University HospitalNCT05917405Written as BusulfanHow we know
- VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07052422Written as Busulfan (Bu)How we know
- Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06613035Written as Intravenous BusulfanHow we know
Showing 20 of 111.
As the comparator · 8 — what is tested is compared with Busulfan
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationRecruitingPhase 2Nantes University HospitalNCT06252870Written as BusulfanHow we know
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationPhase 3Wuhan Union Hospital, ChinaNCT05674539Written as Fludarabine and BusulfanHow we know
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as BusulfanHow we know
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as BusulfanHow we know
- Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Active, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT03597594Written as BusulfanHow we know
- Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedPhase 2medac GmbHNCT02349906Written as BusilvexHow we know
- Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesCompletedPhase 2/3Columbia UniversityNCT01019876Written as BusulfanHow we know
- Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)CompletedPhase 3medac GmbHNCT00822393Written as BusulfanHow we know
Codes
What other systems call Busulfan · ClinicalTrials.gg INT007102
- MeSH (NLM) D002066BusulfanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G1LN9045DKBUSULFANConfirmed FDA, NLM, Wikidata
- RxNorm 1828Confirmed FDA, Wikidata
- Wikidata Q348922busulfanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C321BusulfanOne source FDA
- DrugBank DB01008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002066 | Busulfan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G1LN9045DK | BUSULFAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1828 | — | Confirmed FDA, Wikidata |
| Wikidata | Q348922 | busulfan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C321 | Busulfan | One source FDA |
| DrugBank | DB01008 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.